Trials Sponsors Conditions Drugs Pricing

Conditions

Corneal Epithelial Degeneration

Outcome Measures

Primary Outcomes (1)

Dose Limiting Toxicity
Important Medical Events (ocular) related to study treatment
28 days

Study Arms (4)

TTHX1114 Dose Level 1

EXPERIMENTAL

TTHX1114(NM141) Ophthalmic Solution (DL1): 1 drop (gtt) to the Study Eye (SE) twice daily for a total of 7 days

Drug: TTHX1114(NM141) Ophthalmic Solution

TTHX1114 Dose Level 2

EXPERIMENTAL

TTHX1114(NM141) Ophthalmic Solution (DL2): 1 drop (gtt) to the Study Eye (SE) twice daily for a total of 7 days

Drug: TTHX1114(NM141) Ophthalmic Solution

TTHX1114 Dose Level 3

EXPERIMENTAL

TTHX1114(NM141) Ophthalmic Solution (DL3): 1 drop (gtt) to the Study Eye (SE) twice daily for a total of 7 days

Interventions

TTHX1114(NM141) Ophthalmic SolutionDrug

Eye drop twice daily

TTHX1114 Dose Level 1TTHX1114 Dose Level 2TTHX1114 Dose Level 3TTHX1114 Dose Level 4

Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.

Eligibility Criteria

Age18 Years - 65 Years

Sexall

Healthy VolunteersYes

Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

Female or male, 18 to 65 years of age, Female subjects of child-bearing potential must be non-pregnant
Able to provide voluntary written informed consent

Sponsors & Collaborators

Trefoil Therapeutics, Inc.
Industrylead

Study Sites (1)

Trefoil Clinical Site #132

Cypress, California, 90630, United States

MeSH Terms

Interventions

Ophthalmic Solutions

Intervention Hierarchy (Ancestors)

Pharmaceutical SolutionsSolutionsPharmaceutical PreparationsTherapeutic UsesPharmacologic ActionsChemical Actions and UsesSpecialty Uses of Chemicals

Study Officials

Thomas Tremblay
Trefoil Therapeutics.com
STUDY DIRECTOR

Enrollment

8 participants (actual enrollment reported by the registry).

Study Design

Study Type: interventional
Phase: phase 1
Allocation: NON RANDOMIZED
Masking: NONE
Purpose: OTHER
Intervention Model: SEQUENTIAL
Sponsor Type: INDUSTRY
Responsible Party: SPONSOR

Study Record Dates

First Submitted

March 3, 2023

First Posted

March 15, 2023

Study Start

December 6, 2022

Actual (reported)

Dose Escalation TTHX1114 Ophthalmic Solution

Brief Summary

Registry Overview

Trial Relationships

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (4)

TTHX1114 Dose Level 1

TTHX1114 Dose Level 2

TTHX1114 Dose Level 3

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

TTHX1114 Dose Level 4

You may not qualify if:

Data Sharing

Source record

Locations

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

First Submitted

First Posted

Primary Completion

Study Completion

Conditions

Outcome Measures

Primary Outcomes (1)

Study Arms (4)

TTHX1114 Dose Level 1

TTHX1114 Dose Level 2

TTHX1114 Dose Level 3

Interventions

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

MeSH Terms

Interventions

Intervention Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

TTHX1114 Dose Level 4

You may not qualify if:

Data Sharing

Source record

Locations